John Leonard, MD of Weill Cornell Medicine discusses follicular lymphoma.
Follicular lymphoma is the second most common non-Hodgkin lymphoma accounting for approximately 15% of all lymphomas in North America. Presentation of follicular lymphoma includes asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions of the lymph nodes and usually waxing and waning of the lymph nodes as well.
Treatment for follicular lymphoma is often chemotherapy or radiation therapy, though other treatment options are available, such as rituximab, a combination of lenalidomide and rituximab, or PI3K inhibitors. However, all of these treatments have limitations. Fortunately, the FDA has recently announced an accelerated approval of tazemetostat as a treatment for relapsed or refractory follicular lymphoma.
Tazemetostat works by inhibiting the EZH2 mutation of tumors that can be seen in some follicular lymphoma patients. The improvable rate of taking tazemetostat for follicular lymphoma patients with a EZH2 mutation is roughly 70% – as stated by Dr. Leonard – however, the drug has also been approved for follicular lymphoma patients who do not have the EZH2 mutation but have been unsuccessful on other treatments.
To learn more about follicular lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/.